

1 **Restricted sequence variation in *Streptococcus pyogenes* penicillin binding proteins**

2

3 **Authors:**

4 Andrew Hayes^a, Jake A. Lacey^b, Jacqueline M. Morris^a, Mark R. Davies^a, Steven Y.C. Tong^{c,d,#}

5

6 a. Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and
7 Immunity, The University of Melbourne and The Royal Melbourne Hospital, Melbourne, Victoria,
8 Australia

9 b. Doherty Department, The Peter Doherty Institute for Infection and Immunity, The University of
10 Melbourne and The Royal Melbourne Hospital, Melbourne, Victoria, Australia

11 c. Victorian Infectious Disease Service, The Royal Melbourne Hospital, and Doherty Department
12 University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria,
13 Australia

14 d. Menzies School of Health Research, Charles Darwin University, Darwin, Australia

15

16 Running head: *S. pyogenes* PBP sequence variation

17

18 # Address correspondence to Steven Tong; Steven.Tong@mh.org.au

19

20 Abstract word count: 207

21 Main text word count: 1,236

22 **Abstract**

23 A recent clinical report has linked *Streptococcus pyogenes* β -lactam antibiotic resistance to
24 mutations in the Penicillin Binding Protein PBP2x. To determine whether this is an isolated case or
25 reflects a broader prevalence of mutations that might confer reduced β -lactam susceptibility, we
26 investigated the relative frequency of penicillin binding protein (PBP) sequence variation within a
27 global database of 9,667 *S. pyogenes* isolates. We found that mutations in *S. pyogenes* PBPs (PBP2x,
28 PBP1a, PBP1b and PBP2a) occur infrequently across this global database with less than 3 amino acid
29 changes differing between >99% of the global population. Only 4 of the 9,667 strains contained
30 mutations near transpeptidase active sites. The reported PBP2x T553K substitution was not
31 identified. These findings are in contrast to those of 2,520 *S. pneumococcus* sequences where PBP
32 mutations are relatively frequent and are often located in key β -lactam binding pockets. These data,
33 combined with the general lack of penicillin resistance reported in *S. pyogenes* worldwide, suggests
34 that extensive, unknown, constraints restrict *S. pyogenes* PBP sequence plasticity. These findings
35 imply that while heavy antibiotic pressure may select for mutations in the PBPs, there is currently no
36 evidence of such mutations becoming fixed in the *S. pyogenes* population nor that mutations are
37 being sequentially acquired in the PBPs.

38

39 **Importance**

40 Penicillin is the first line therapeutic option for *Streptococcus pyogenes* infections. Despite the global
41 high prevalence of *S. pyogenes* infections and widespread use of penicillin, reports of resistance to
42 penicillin have been incredibly rare. Recently, penicillin resistance was detected in two clinical *S.*
43 *pyogenes* isolates with accompanying mutations in the active site of the penicillin binding protein
44 PBP2x, raising concerns that penicillin resistance may become more widespread. We screened a
45 global database of *S. pyogenes* genome sequences to investigate the frequency of penicillin binding
46 protein (PBP) mutations, identifying that PBP mutations are uncommon relative to *Streptococcus*
47 *pneumoniae*. These findings support clinical observations that penicillin resistance is rare in *S.*

- 48 *pyogenes*, and suggest that there are considerable constraints on *S. pyogenes* PBP sequence
- 49 variation.

50 INTRODUCTION

51 *Streptococcus pyogenes* (Group A *Streptococcus*, GAS) has previously been understood to be
52 uniformly susceptible to β -lactam antibiotics (1). Two *S. pyogenes* isolates with elevated minimum
53 inhibitory concentrations (MIC) to β -lactam antibiotics have recently been reported (2). Both isolates
54 were molecularly typed as *emm* 43.4 and had a penicillin binding protein PBP2x missense mutation
55 (T553K) at the transpeptidase active site which was associated with an 8-fold and 3-fold increased
56 MIC to ampicillin and cefotaxime respectively compared to closely related isolates without the
57 PBP2x mutation. In contrast to *S. pyogenes*, reduced susceptibility to β -lactams has been widely
58 reported in *S. pneumoniae* and is strongly associated with sequence variation in PBPs (3, 4).
59 Using GAS genome sequences from global sources, we sought to determine the prevalence of
60 substitutions across the transpeptidase domains of the GAS PBPs (PBP2x, PBP1a, PBP2a and PBP1b)
61 in comparison with *S. pneumoniae* (which shares PBP2x and PBP1a).

62

63 METHODS

64 We obtained publicly available genome sequence data for 9,667 *S. pyogenes* isolates from the short-
65 read archive (**Supplementary Table 1**). We assembled genomes using shovill v.1.0.9
66 (<https://github.com/tseemann/shovill>) with an underlying SKESA v.2.3.0 assembler (5). Using the β -
67 lactam susceptible *S. pyogenes* serotype M3 strain ATCC BAA-595/MGAS315 as a reference, we
68 determined the presence, amino acid sequence and alignment (6) of each of PBP2x, PBP1a, PBP1b
69 and PBP2a in each genome with the screen_assembly script (7) and BlastP parameters of 100%
70 coverage and 90% identity.

71 To compare the conservation of the transpeptidase active site motifs across streptococcal species,
72 full length PBP2x protein sequences of *S. pyogenes* serotype M3 strain ATCC BAA-595/MGAS315
73 (NC_004070.1), *S. pneumoniae* strain ATCC BAA-255/R6 (NC_003098.1), *S. agalactiae* strain 2603V/R
74 (NC_004116.1), and the *S. dysgalactiae* subspecies *equisimilis* (SDSE) strain RE378 (NC_018712.1)

75 reference genomes were aligned using Clustal Omega (8, 9). The percentage sequence similarity was
76 compared using Blosum62 with threshold 1 in Geneious Prime (10).

77 To investigate the inferred crystal structure location of *S. pyogenes* PBP2x mutations relative to the
78 *S. pneumoniae* orthologue, *S. pyogenes* PBP2x sequence variations were plotted onto the *S.*
79 *pneumoniae* PBP2x crystal structure bound to oxacillin (PDB: 5OIZ) (11). Sequence conservation as
80 determined by the frequency (for *S. pyogenes*) and percentage (for *S. pneumoniae*) of variant amino
81 acids compared to the consensus was rendered onto the PBP2x crystal structure using UCSF Chimera
82 (12).

83 We defined the PBP2x and PBP1a transpeptidase regions as that used in an assessment of 2,520
84 invasive *S. pneumoniae* isolates by Li et al (3) and determined and plotted the number of pairwise
85 amino acid differences within these regions using Distances Matrix in Geneious Prime (10) and
86 ggplot2 in R version 3.6.1 (13). Similarly, we also assessed the conservation of PBP1b and PBP2a
87 proteins for the 9,667 *S. pyogenes* genomes, and the transpeptidase region of PBP2b for *S.*
88 *pneumoniae*.

89

90 **RESULTS**

91 We collated 9,667 *S. pyogenes* genome sequences, representing 115 different *emm* types and 321
92 multi-locus sequence types (**Supplementary Table 1, Supplementary Files 1-4**). These genome
93 sequences were mostly from datasets from the United Kingdom and United States that focused on
94 invasive disease (14-24).

95

96 Mutations in the penicillin binding proteins (PBPs) have been associated with reduced β -lactam
97 susceptibility for *S. pneumoniae* (3), *S. agalactiae* (25), *S. dysgalactiae* (26), and now *S. pyogenes* (2).
98 A comparison of PBP2x between β -lactam susceptible reference genomes of *S. pyogenes*, *S.*
99 *pneumoniae*, *S. agalactiae*, and SDSE demonstrated a high level of inter-species conservation (>72%
100 similarity, **Supplementary Figure 1 and Supplementary Table 2**). In *S. pneumoniae*, substitutions at

101 the PBP2x transpeptidase active site (SXXK, SXN, and KSTG) result in reduced β -lactam susceptibility.
102 These three motifs were conserved across the four species (**Supplementary Figure 1**).
103 Given the similarity between PBP2x of *S. pneumoniae* and *S. pyogenes* (73.4% similarity,
104 **Supplementary Table 1**), we mapped the conservation of residues from the alignment of 9,667 *S.*
105 *pyogenes* PBP2x onto the crystal structure of *S. pneumoniae* PBP2x (**Figure 1**). The transpeptidase
106 active site motifs are SXXK at positions 340-343 in *S. pyogenes* (positions 337-340 in *S. pneumoniae*),
107 SXN at positions 399-401 in *S. pyogenes* (positions 395-397 in *S. pneumoniae*), and KSGT at positions
108 550-553 in *S. pyogenes* (positions 547-550 in *S. pneumoniae*). There were 105 unique amino acid
109 sequence variants of the *S. pyogenes* PBP2x sequence with no major frameshifts or premature stop
110 codons (**Supplementary File 1**). We found no instances of the T553K substitution in the PBP2x KSGT
111 motif as reported in the recent *S. pyogenes* β -lactam resistant isolates (2). Only four *S. pyogenes*
112 isolate sequences (0.04%) had substitutions within the transpeptidase active site motifs of PBP2x
113 (**Figure 1** and **Table 1**) corresponding to STMK to SAMK and STMK to STIK. These changes may not
114 have a phenotypic effect on penicillin susceptibility as STIK has been recently reported in a penicillin-
115 susceptible isolate (GASAR0057) (17). Furthermore, no amino acid substitutions were found in the
116 active site motifs of *S. pyogenes* PBP1a. In comparison, using population data from Li et al (3), *S.*
117 *pneumoniae* had active site motif variants in 639/2,520 (25.3%) isolates for PBP2x and 445/2,520
118 (17.7%) for PBP1a (**Table 1**). A large proportion of *S. pneumoniae* substitutions mapped to areas near
119 to the active site (**Supplementary Figure 2**).
120 For *S. pneumoniae*, the number of substitutions across the whole transpeptidase domain of PBPs has
121 been associated with penicillin resistance. Li et al. (3) found that penicillin MICs increased as the
122 total number of divergent (defined as >10% amino acids different) transpeptidase domains of PBP2x,
123 PBP1a and PBP2b increased from 0 to 3. For *S. pyogenes* we used the most common amino acid
124 sequences of PBP2x and PBP1a as our reference and for *S. pneumoniae* a previously defined
125 wildtype as the reference (3). There were considerably fewer PBP2x and PBP1a transpeptidase
126 domains with multiple substitutions for *S. pyogenes* compared to *S. pneumoniae* (**Figure 2**). No *S.*

127 *pyogenes* strains had sufficient mutations to reach the 10% threshold. For *S. pneumoniae*, 18.3%
128 (462 of 2,520 strains) and 19.2% (485 of 2,520 strains) contained divergent PBP2x and PBP1a
129 transpeptidase domains respectively (**Figure 2**). This pattern of greater conservation of *S. pyogenes*
130 PBPs was also observed for PBP1b and PBP2a in *S. pyogenes* compared to PBP2b in *S. pneumoniae*
131 (**Supplementary Figure 3**).

132

133 **DISCUSSION**

134 We found no evidence that mutations are present in the β -lactam binding site KSGTAQ motif of
135 PBP2x among 9,667 *S. pyogenes* genome sequences. Only four isolates contained mutations in the
136 transpeptidase active sites of PBP2x and PBP1a. Although the report of two *S. pyogenes* isolates with
137 reduced β -lactam susceptibility associated with *pbp2x* mutations is concerning (2), our findings
138 provide reassurance that these are extremely limited, and perhaps unique, occurrences at this stage.
139 We found a high degree of conservation of GAS PBP2x and PBP1a at transpeptidase active sites and
140 across the broader transpeptidase domains. In comparison, PBP2x and PBP1a for *S. pneumoniae*
141 were far less conserved, suggesting that there are strong evolutionary constraints in these domains
142 for *S. pyogenes* that is not the case for *S. pneumoniae*. Studies of penicillin-resistant *S. pyogenes*
143 generated through mutagenesis (27) or serial passage in penicillin containing medium (28),
144 demonstrated that mutants with raised penicillin MICs appeared to have alterations in PBPs with
145 reduced penicillin affinity (27). Notably mutants grow more slowly, have aberrant colony
146 morphology compared to wild type strains (27), and are avirulent with a decrease in M protein
147 production (28). These laboratory experiments, together with the absence of naturally occurring
148 isolates with greater than five amino acid substitutions in PBP2x or PBP1a, strongly suggest that
149 changes to the PBPs are associated with a significant fitness cost.

150

151 **ACKNOWLEDGEMENTS**

152 This work was supported by an Australian National Health and Medical Research Council (NHMRC)
153 project grant #1098319. SYCT is a NHMRC Career Development Fellow (#1145033). MRD is the
154 recipient of a University of Melbourne C. R. Roper Fellowship. The funders had no role in study
155 design, data collection and interpretation, or the decision to submit the work for publication.

156 **References**

- 157 1. **Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA, Gotschlich E, Kaplan**
158 **EL, McCarty M, Opal SM, Roberts RB, Tomasz A, Wachtfogel Y.** 1998. Why have group A
159 streptococci remained susceptible to penicillin? Report on a symposium. *Clin Infect Dis*
160 **26:1341-1345.**
- 161 2. **Vannice K, Ricaldi J, Nanduri S, Fang FC, Lynch J, Bryson-Cahn C, Wright T, Duchin J, Kay M,**
162 **Chochua S, Van Beneden C, Beall B.** 2019. *Streptococcus pyogenes* *pbp2x* Mutation Confers
163 Reduced Susceptibility to beta-lactam antibiotics. *Clin Infect Dis* doi:10.1093/cid/ciz1000.
- 164 3. **Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE, Jr., Walker H, Hawkins PA, Tran T, Whitney CG,**
165 **McGee L, Beall BW.** 2016. Penicillin-Binding Protein Transpeptidase Signatures for Tracking
166 and Predicting beta-Lactam Resistance Levels in *Streptococcus pneumoniae*. *MBio* **7.**
- 167 4. **Dewe TCM, D'Aeth JC, Croucher NJ.** 2019. Genomic epidemiology of penicillin-non-
168 susceptible *Streptococcus pneumoniae*. *Microb Genom* **5.**
- 169 5. **Souvorov A, Agarwala R, Lipman DJ.** 2018. SKESA: strategic k-mer extension for scrupulous
170 assemblies. *Genome Biol* **19:153.**
- 171 6. **Edgar RC.** 2004. MUSCLE: multiple sequence alignment with high accuracy and high
172 throughput. *Nucleic Acids Res* **32:1792-1797.**
- 173 7. **Davies MR, McIntyre L, Mutreja A, Lacey JA, Lees JA, Towers RJ, Duchene S, Smeesters PR,**
174 **Frost HR, Price DJ, Holden MTG, David S, Giffard PM, Worthing KA, Seale AC, Berkley JA,**
175 **Harris SR, Rivera-Hernandez T, Berking O, Cork AJ, Torres R, Lithgow T, Strugnell RA,**
176 **Bergmann R, Nitsche-Schmitz P, Chhatwal GS, Bentley SD, Fraser JD, Moreland NJ,**
177 **Carapetis JR, Steer AC, Parkhill J, Saul A, Williamson DA, Currie BJ, Tong SYC, Dougan G,**
178 **Walker MJ.** 2019. Atlas of group A streptococcal vaccine candidates compiled using large-
179 scale comparative genomics. *Nat Genet* **51:1035-1043.**

- 180 8. **Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert**
181 **M, Soding J, Thompson JD, Higgins DG.** 2011. Fast, scalable generation of high-quality
182 protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* **7**:539.
- 183 9. **Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R.** 2010. A new
184 bioinformatics analysis tools framework at EMBL-EBI. *Nucleic Acids Res* **38**:W695-699.
- 185 10. **Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A,**
186 **Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A.** 2012. Geneious
187 Basic: an integrated and extendable desktop software platform for the organization and
188 analysis of sequence data. *Bioinformatics* **28**:1647-1649.
- 189 11. **Bernardo-Garcia N, Mahasenan KV, Batuecas MT, Lee M, Hesek D, Petrackova D,**
190 **Doubrovova L, Branny P, Mobashery S, Hermoso JA.** 2018. Allostery, Recognition of Nascent
191 Peptidoglycan, and Cross-linking of the Cell Wall by the Essential Penicillin-Binding Protein 2x
192 of *Streptococcus pneumoniae*. *ACS Chem Biol* **13**:694-702.
- 193 12. **Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE.** 2004.
194 UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem*
195 **25**:1605-1612.
- 196 13. **R Core Team.** 2019. R: A language and environment for statistical computing. R Foundation
197 for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.
- 198 14. **Athey TB, Teatero S, Sieswerda LE, Gubbay JB, Marchand-Austin A, Li A, Wasserscheid J,**
199 **Dewar K, McGeer A, Williams D, Fittipaldi N.** 2016. High Incidence of Invasive Group A
200 *Streptococcus* Disease Caused by Strains of Uncommon emm Types in Thunder Bay, Ontario,
201 Canada. *J Clin Microbiol* **54**:83-92.
- 202 15. **Chalker V, Jironkin A, Coelho J, Al-Shahib A, Platt S, Kapatai G, Daniel R, Dhami C,**
203 **Laranjeira M, Chambers T, Guy R, Lamagni T, Harrison T, Chand M, Johnson AP,**
204 **Underwood A, Scarlet Fever Incident Management T.** 2017. Genome analysis following a
205 national increase in Scarlet Fever in England 2014. *BMC Genomics* **18**:224.

- 206 16. **Bergin SM, Periaswamy B, Barkham T, Chua HC, Mok YM, Fung DSS, Su AHC, Lee YL, Chua**
207 **MLI, Ng PY, Soon WJW, Chu CW, Tan SL, Meehan M, Ang BSP, Leo YS, Holden MTG, De P,**
208 **Hsu LY, Chen SL, de Sessions PF, Marimuthu K.** 2018. An Outbreak of *Streptococcus*
209 *pyogenes* in a Mental Health Facility: Advantage of Well-Timed Whole-Genome Sequencing
210 Over emm Typing. *Infect Control Hosp Epidemiol* **39**:852-860.
- 211 17. **Turner CE, Bedford L, Brown NM, Judge K, Torok ME, Parkhill J, Peacock SJ.** 2017.
212 Community outbreaks of group A *Streptococcus* revealed by genome sequencing. *Sci Rep*
213 **7**:8554.
- 214 18. **Coelho JM, Kapatai G, Jironkin A, Al-Shahib A, Daniel R, Dhimi C, Laranjeira AM, Chambers**
215 **T, Phillips S, Tewolde R, Underwood A, Chalker VJ.** 2019. Genomic sequence investigation
216 *Streptococcus pyogenes* clusters in England (2010-2015). *Clin Microbiol Infect* **25**:96-101.
- 217 19. **Dickinson H, Reacher M, Nazareth B, Eagle H, Fowler D, Underwood A, Chand M, Chalker**
218 **V, Coelho J, Daniel R, Kapatai G, Al-Shahib A, Puleston R.** 2019. Whole-genome sequencing
219 in the investigation of recurrent invasive group A *streptococcus* outbreaks in a maternity
220 unit. *J Hosp Infect* **101**:320-326.
- 221 20. **Davies MR, Holden MT, Coupland P, Chen JH, Venturini C, Barnett TC, Zakour NL, Tse H,**
222 **Dougan G, Yuen KY, Walker MJ.** 2015. Emergence of scarlet fever *Streptococcus pyogenes*
223 emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance.
224 *Nat Genet* **47**:84-87.
- 225 21. **Ben Zakour NL, Davies MR, You Y, Chen JH, Forde BM, Stanton-Cook M, Yang R, Cui Y,**
226 **Barnett TC, Venturini C, Ong CL, Tse H, Dougan G, Zhang J, Yuen KY, Beatson SA, Walker**
227 **MJ.** 2015. Transfer of scarlet fever-associated elements into the group A *Streptococcus*
228 M1T1 clone. *Sci Rep* **5**:15877.
- 229 22. **Chochua S, Metcalf BJ, Li Z, Rivers J, Mathis S, Jackson D, Gertz RE, Jr., Srinivasan V,**
230 **Lynfield R, Van Beneden C, McGee L, Beall B.** 2017. Population and Whole Genome

- 231 Sequence Based Characterization of Invasive Group A Streptococci Recovered in the United
232 States during 2015. *MBio* **8**.
- 233 23. **Kapatai G, Coelho J, Platt S, Chalker VJ.** 2017. Whole genome sequencing of group A
234 *Streptococcus*: development and evaluation of an automated pipeline for emm gene typing.
235 *PeerJ* **5**:e3226.
- 236 24. **Lynskey NN, Jauneikaite E, Li HK, Zhi X, Turner CE, Mosavie M, Pearson M, Asai M,**
237 **Lobkowitz L, Chow JY, Parkhill J, Lamagni T, Chalker VJ, Sriskandan S.** 2019. Emergence of
238 dominant toxigenic M1T1 *Streptococcus pyogenes* clone during increased scarlet fever
239 activity in England: a population-based molecular epidemiological study. *Lancet Infect Dis*
240 **19**:1209-1218.
- 241 25. **Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr., Schrag S, Nizet V, Beall BW.** 2008. Point
242 mutation in the group B streptococcal *pbp2x* gene conferring decreased susceptibility to
243 beta-lactam antibiotics. *Antimicrob Agents Chemother* **52**:2915-2918.
- 244 26. **Fuursted K, Stegger M, Hoffmann S, Lambertsen L, Andersen PS, Deleuran M, Thomsen**
245 **MK.** 2016. Description and characterization of a penicillin-resistant *Streptococcus*
246 *dysgalactiae* subsp. *equisimilis* clone isolated from blood in three epidemiologically linked
247 patients. *J Antimicrob Chemother* **71**:3376-3380.
- 248 27. **Gutmann L, Tomasz A.** 1982. Penicillin-resistant and penicillin-tolerant mutants of group A
249 Streptococci. *Antimicrob Agents Chemother* **22**:128-136.
- 250 28. **Rosendal K.** 1958. Investigations of Penicillin-Resistant Streptococci belonging to Group A.
251 *Acta Pathol et Microbiol Scand* **42**:181-188.
- 252
- 253

254 **Table 1:** Percentage of transpeptidase sequences with variation in the SXXK, SXN or K(T/S)G motifs
 255 of the transpeptidase active sites in PBP1a and PBP2x for *S. pneumoniae* and *S. pyogenes*.
 256

	<i>S. pneumoniae</i>	<i>S. pyogenes</i>
Motif	(n=2,520)	(n=9,667)
	Variants (%)	Variants (%)
<u>PBP1a</u>		
STMK*	445 (17.7)	0 (0)
SRN	0 (0)	0 (0)
KTG(T)	0 (0)	0 (0)
<u>PBP2x</u>		
STMK*	639 (25.3)	4 (0.04)
SSN	0 (0)	0 (0)
KSG(T)**	0 (3) (0 (0.1))	0 (0)

257

258 * the transpeptidase domain sequences as defined in Li et al 2016 were truncated between the S
 259 and T of the S//TMK

260 ** This table does not include the two T553K sequences reported to be associated with β -lactam
 261 resistance in *S. pyogenes* in Vannice et al.

262 **Figure 1: Global amino acid variation of *Streptococcus pyogenes* PBP2x mapped against the crystal**
263 **structure of *Streptococcus pneumoniae* PBP2x**

264

265 Crystal structure of PBP2X from *S. pneumoniae* bound to oxacillin (Blue) with residue conservation of
266 *S. pyogenes* PBP2x mapped to surface. 9,667 *S. pyogenes* sequences were mapped to the 5OIZ
267 structure sequence and frequency of conservation amongst *S. pyogenes* strains determined.
268 Conservation was then mapped to surface residues and colour gradient applied. Black residues
269 represent regions absent in the alignment due to absence of sequence relative to the *S. pneumoniae*
270 crystal structure. Thresholds were chosen to represent differing orders of magnitude for
271 conservation with thresholds set at orders of magnitude (0, 1, 10, 100, 1000 sequences varying at
272 the residue). **Inset:** ribbon diagram of binding pocket motifs SSN, STMK and KSG with position of
273 mutated residue (T553K) highlighted (yellow). Mutations were observed in the STMK motif in 4 of
274 the 9,667 sequences.

275 **Figure 2: Amino acid differences of the transpeptidase domains of PBP2x and PBP1a**

276

277 The percentage of isolates with changes in the transpeptidase domains of A) PBP2x and B) PBP1a,

278 relative to penicillin susceptible references in *Streptococcus pneumoniae* (blue, n= 2,520) and *S.*

279 *pyogenes* (red, n= 9,667). Sequences that are >10% divergent (indicated by dotted vertical lines)

280 have been associated with increased penicillin minimum inhibitory concentrations in *S. pneumoniae*.

281 **Supplementary Table 1:** Strain list with *emm* and MLST types, amino acid sequence and alleles of
282 PBP2x, PBP1a, PBP1b and PBP2a.
283
284 **Supplementary Table 2:** The similarity matrix between PBP2x for four *Streptococcus* species as
285 determined by BLOSUM62 threshold ≥ 1 .

286 **Supplementary Figure 1: PBP2x alignment for *S. pyogenes*, *S. pneumoniae*, *S. agalactiae*, and *S.***

287 ***dysgalactiae subspecies equisimilis***

288 Clustal Omega multiple sequence alignment of PBP2x between of *S. pyogenes* serotype M3 strain

289 ATCC BAA-595/MGAS315 (genome reference NC_004070.1, protein reference WP_011106648.1), *S.*

290 *pneumoniae* strain ATCC BAA-255/R6 (genome reference NC_003098.1, protein reference

291 NP_357898.1), *S. agalactiae* strain 2603V/R (genome reference NC_004116.1, protein reference

292 NP_687322.1), and the *S. dysgalactiae subspecies equisimilis* (labelled *S. equisimilis*) strain RE378

293 (genome reference NC_018712.1, protein reference WP_015017311.1). The three transpeptidase

294 active site motifs are highlighted in bold text and underlined. Fully conserved amino acids are

295 denoted by an asterix, a strongly conserved protein is denoted by a colon and proteins that are




296 weakly conserved are denoted by a full-stop.

297 **Supplementary Figure 2: *Streptococcus pneumoniae* transpeptidase domain sequences mapped to**
298 **the crystal structure of PBP2x**


299 Crystal structure of PBP2X from *S. pneumoniae* bound to oxacillin (Blue) with residue conservation of
300 the 118 transpeptidase variants identified by Li et al (2016) mapped to surface. The 118 non-
301 redundant transpeptidase sequences identified by Li et al (2016) were aligned using MUSCLE aligner
302 and the conservation of sites mapped to the surface of PDB 5OIZ and colour gradient applied. Black
303 residues represent regions absent in the alignment due to not being part of the transpeptidase
304 domain. Thresholds were chosen to represent the range of sequence variation in the unique
305 sequences but unlike the *S. pyogenes* dataset does not represent frequency of the variants within
306 the population. **Inset:** ribbon diagram of binding pocket motifs SSN, STMK and KSG with position of
307 mutated residue (T550K) highlighted.

308 **Supplementary Figure 3:** Amino acid differences of the complete PBP1b and PBP2a for *S. pyogenes*
309 and the transpeptidase domain of PBP2b for *S. pneumoniae*. The length of the complete PBP1b was
310 766 amino acids and PBP2a was 756 amino acids for *S. pyogenes*. The PBP2b transpeptidase domain
311 was 280 amino acids in *S. pneumoniae*. The percentage of isolates with changes relative to penicillin
312 susceptible references in the full protein of *S. pyogenes* (red; n= 9,667) and in the transpeptidase
313 domains of *S. pneumoniae* (blue; n=2,520). For A) PBP1b (*S. pyogenes*), B) PBP2a (*S. pyogenes*) and
314 C) PBP2b (*S. pneumoniae*). Sequences that are >10% divergent are indicated by dotted vertical lines.

variants



A



B

